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C atheter ablation has become an essential therapeutic option for the treatment of ventricular arrhythmias. For premature ventricular complex (PVC)/ventricular tachycardia (VT) ablation in structurally normal hearts, recently reported success rates are as high as 80% for right ventricular outflow tract ablation, and 60% to 100% for left-sided ablation. 1 Procedural safety and efficacy have improved with better understanding of surface ECG predictors of PVC origin location, refined electroanatomic mapping techniques, evermore precise electroanatomic activation maps to localize PVC origins, automated techniques to quantify the fidelity of pacemapping surface QRS morphologies, improved ablation technology, and intracardiac ultrasound. 1 Although these advancements might lead us to believe we have entered a golden age for interventional electrophysiology, we as electrophysiologists and cardiologists need to continue our vigilance for serious complications arising from these invasive procedures.
In this issue of Circulation, Whitman et al 2 evaluate the incidence of subclinical brain emboli in a small series of patients with structurally normal hearts undergoing endocardial catheter ablation for PVCs and VT. Electrophysiologists frequently map and ablate in the left ventricular (LV) endocardial and aortic root spaces, 1, 3, 4 with an assumption that, with proper intravenous systemic anticoagulation, the risk of systemic embolization phenomenon is acceptably low. In addition, with transseptal procedures, the risk of air or thrombus entry to the systemic circulation via the transseptal sheath is minimized through continuous saline flush through the long sheaths, or by retracting the sheath back to the right atrium. More recently, with the near-universal adoption of open-irrigated catheters, it is assumed that the risks of catheter char, coagulum, or thrombus are mitigated, although there are few clinical data to support this claim.
It turns out that we know very little about whether any of these measures are truly effective in minimizing systemic embolization. Reported systemic embolization complications are low for LV 1, 3, 4 and for left atrial catheter ablation procedures, 5 but may be underestimated because the events were based only on clinical symptoms. Silent MRI-confirmed central nervous system embolic events have a reported incidence as high as 38% in left atrial catheter ablation, [5] [6] [7] [8] 22% for aortic valve-crossing procedures, and 10% for routine coronary angiography. 9, 10 The mechanisms for emboli postulated in these cases are heterogeneous, and it is not clear how these data apply to patients undergoing LV PVC/VT ablation who do not have the same risk factors. With atrial fibrillation ablation, factors including left atrial appendage stasis, a significantly larger area of endocardial tissue ablated, and increased underlying stroke risk differentiate it from LV PVC/VT ablation. Patients undergoing cardiac catheterization typically have significant comorbidities and increased stroke risk attributable to atherosclerotic risk.
The Sound of Silence How Much Noise Should We Make About Postablation Silent Strokes?
For the patient population evaluated in this article, ie, those with no or minimal underlying structural heart disease and fewer stroke risk factors undergoing ablation for PVCs or VT, reported overt clinical neurological event rates are very low or absent. 1, 3, 4 Whitman et al are the first to evaluate the incidence of subclinical brain embolization in this population, finding MRI evidence in 7 of 12 (58%) patients undergoing left-sided ablation. As expected, the 6 control patients undergoing right-sided ablation had no subclinical or clinical emboli; pulmonary embolism rates were not evaluated. All but one of the patients undergoing LV ablation had access to the LV obtained via a retrograde aortic approach.
This central result of this study is both surprising and alarming. Could electrophysiologists be unknowingly causing subclinical emboli unacceptably often, while believing we are reliably avoiding clinically significant events?
The higher than expected incidence of emboli may in part be explained by improved detection through better neuroimaging techniques such as the stronger 3T magnet in comparison with the 1.5T magnet used in prior studies. [5] [6] [7] [8] [9] [10] If this possible underestimation of events is indeed alarming to the reader, it should be emphasized that the clinical significance of these emboli remains uncertain. Silent brain infarcts are those diagnosed incidentally on neuroimaging but not associated with any overt acute clinical symptoms. The majority are punctate subcortical lesions, often associated with small-vessel ischemia, although a small percentage may be cortically based, typically from cardioembolism. Population-based studies associate unprovoked silent infarcts with increased risk of symptomatic stroke, but, because of limited data, the current guidelines recommend screening and management of traditional cerebrovascular risk factors as is done for primary, rather than secondary, stroke prevention. 11 When the silent infarct is provoked from a cardiac procedure, we are even less certain if there is a true risk of future recurrence that would warrant any postprocedural pharmacological intervention. Regardless of the cause, there is also controversy whether there are irreversible neurocognitive sequelae of these covert infarcts, or if they are truly silent and selfresolving. 12 Longer-term data are needed to better characterize the clinical significance of these "silent" emboli, and cognitive testing should increasingly be included as a functional outcome measure in electrophysiology and stroke studies.
Perhaps an analogous scenario is the dreaded risk of atrioesophageal fistula resulting from atrial fibrillation ablation. For this complication, we understand the event rate to be low, yet a surprisingly high incidence of subclinical esophageal injury is seen when we look for it. 13 Similarly, this provocative article suggests that with LV ablation, we are possibly seeing very few clinical events despite a high incidence of subclinical events; and, most distressing, we have a poor understanding of the pathophysiology of these embolic events.
The immediate question raised by this study is, what are the underlying mechanism(s) for the embolization phenomenon observed? The basic hypothesis is that procedural endothelial injury caused by ablation unleashes the coagulation cascade, leading to localized thrombus.
14 Additional contributors may include air embolism via infusion from open irrigated catheters, intracardiac thrombus, catheter-based thrombus, or atheroemboli, particularly from aortic arch scraping. [5] [6] [7] [8] [9] [10] [11] [12] Interestingly, in this study, the majority of retrograde aortic procedures were associated with emboli, whereas the single reported transseptal procedure had no emboli. It is clear that with a single transseptal case, it is impossible to draw useful conclusions, but the emboli with a retrograde aortic approach might result from mechanical trauma to aortic arch atheroma.
In this study, the authors attempted to evaluate at least some of these potential embolic sources. Clinical history and femoral arteriograms demonstrated a low likelihood of peripheral artery disease; however, there was no systematic evaluation for aortic atheroma for which this population had moderate risk. The reported neuroimaging was not consistent with "watershed" hypoperfusion that may be seen periprocedurally. The pattern of multifocal punctate embolic cortical and subcortical ischemia favors a nonspecific cardioembolic source. A detailed tracking of periprocedural systemic anticoagulation was performed, demonstrating adequate anticoagulation, at least to the standards of common practice. There were no reports of abnormal ablation parameters, including evidence of steam pops or excessive impedance changes. However, none of the above observations can definitively exclude any specific source of embolization.
So where do we go from here? Validation of this article's findings in larger populations is needed. We need to clarify the etiology of these emboli, which will influence preventative targets. One may consider the use of periprocedural microemboli detection with transcranial Doppler to characterize exactly when they begin to occur and if they are truly spared in the transseptal approach. Once the likely source(s) have been identified, we need to determine whether these silent emboli have any important long-term sequelae, and whether interventions to limit these phenomena are necessary and effective. It is not clear, for example, that the authors' intervention of initiating aspirin postprocedure is useful, because there does not seem to be a high recurrence risk. Collaboration with vascular neurology colleagues will be a critical part of future investigation and therapies.
This study population is one of the healthier groups among those undergoing endocardial catheter ablation for LV arrhythmias. One might postulate that patients with underlying structural heart disease and other risk factors for stroke may be at even higher risk of embolic phenomena; that population certainly warrants evaluation. As our field moves toward permissiveness in obtaining MRIs in patients with implanted devices, 15 there should be fewer barriers to similarly evaluating these additional patient populations, where the prevalence of in situ implantable cardiac defibrillators is much higher. However, including functional/clinical outcomes will be necessary to interpret the significance of these radiographic outcomes.
When it comes to the potential risk of embolic complications, the stakes are high, particularly in patients whose indication for the procedure is to relieve symptoms. A central nervous system event could be a catastrophic complication. This article should serve as a wake-up call to our field, perhaps a reminder that we cardiologists and electrophysiologists need to continue our vigilance for risks of significant harm to our patients from invasive procedures. We as a field need to collaborate with our vascular neurology colleagues to determine whether these "silent" emboli are a clinically important phenomena requiring intervention, or whether we are simply making too much noise about a problem that can remain silent.
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